Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 18Other hematologic neoplasm 14Plasma cell 12Thoracic 10Head & Neck 6Gastrointestinal 6Breast 6Genitourinary 5Myeloid 4Dermatologic 4Tumor-Agnostic 3Gynecologic 3CNS 3Other solid neoplasm 2Other 2Sarcoma 1Other neoplasm 1Endocrine 1

Conditions

Neurofibromatosis 1 1Melanoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Brain Neoplasms 1Adenocarcinoma 1

Interventions

Temozolomide 610Radiotherapy 388Bevacizumab 254Magnetic Resonance Spectroscopy 203Cyclophosphamide 177Carboplatin 159Radiosurgery 146Etoposide 132Radiation 121Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 82Lomustine 81Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Acetaminophen × CNS × Clear all
NCT01607905 2023-01-26

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

Karyopharm Therapeutics Inc

Phase 1 Completed
192 enrolled 29 charts
CNSDermatologicGastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Glioblastoma, Melanoma, Colorectal Neoplasms

NCT04313374 2020-03-18

Integrated Pulmonary Index and Opioid Based Patient Controlled Analgesia

Istanbul University

Phase 4 Completed
90 enrolled
CNS

Brain Neoplasms

NCT03649165 2018-11-08

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

AstraZeneca

Phase 1 Completed
24 enrolled
CNS

Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡